Viatris opened higher at $19.29, compared with its previous close of $19.20. In the last trading session, the stock traded between $19.04 and $19.51. It showed a sideways intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Viatris is now worth
$ 143.03
giving a profit of
$ 43.03 (43.03%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
55.56%
Hold
33.33%
Sell
11.11%
Markets Today
Today's Change
$-0.11 (-0.55%)
Day High
$19.51
Day Low
$19.04
Day Open
$19.29
Prev Close
$19.20
Volume
35,01,696
1W Return
3.33%
1M Return
5.38%
3M Return
7.07%
6M Return
27.56%
1Y Return
85.93%
Fundamentals
Market Cap ($ Mn)
21,932
PE Ratio
-
PB Ratio
1.32
PEG Ratio
-
ROE
-22.03%
ROCE
-9.95%
EPS (TTM)
$-0.10
Investment Returns
1 Week
3.33%
1 Month
5.38%
3 Months
7.07%
6 Months
27.56%
9 Months
46.10%
Financials
Quarterly
All values in $ Mn
3.3K
Mar 25
3.6K
Jun 25
3.8K
Sep 25
3.7K
Dec 25
3.5K
Mar 26
3.8K
Jun 26
Updates
21Oct
JP Morgan raises Viatris price target to $20, maintains neutral
JP Morgan raises Viatris price target to $20. Rating maintained at Neutral by analyst Chris Schott. Previous price target was set at $18.
9 days ago
8Oct
Viatris to acquire Pacira BioSciences for $1.65 billion
Viatris agreed to acquire Pacira BioSciences for $1.65 billion in cash. Pacira generated $746 million in revenue and $177 million in adjusted EBITDA in the last 12 months. The deal adds EXPAREL and ZILRETTA to Viatris' non-opioid pain management portfolio. Viatris plans to fund most of the purchase using excess cash and short-term borrowing. The acquisition is expected to close by the end of 2026.
22 days ago
16Sep
Piper Sandler raises Viatris price target to $13, keeps Neutral
Piper Sandler raises Viatris price target to $13 from $12. Analyst David Amsellem maintains Neutral rating. Adjustment reflects updated valuation metrics.
1mo ago
16Sep
Viatris secures Japan approval for WAKIX to treat narcolepsy and sleepiness
Japan approves WAKIX for narcolepsy and OSAS-related sleepiness. First histamine H3 receptor antagonist approved in Japan for these conditions. Designated as orphan drug for narcolepsy in Japan. Licensed exclusively to Viatris for the Japanese market.
1mo ago
29Jul
Viatris secures FDA approval for Gwyn Lo contraceptive patch
Viatris Inc. has received FDA approval for Gwyn Lo, a once-weekly contraceptive patch with low-dose estrogen, via the 505(b)(2) pathway. Supported by Phase 3 Luminous Study data showing a Pearl Index of 4.14 and robust adhesion, the product targets women with BMI below 30 kg/m². Commercial availability is expected later this year.
3mo ago
29Jun
Analysts rate 3 high-dividend health care stocks
Analysts have provided updated ratings and price targets for three health care stocks offering high dividend yields: Viatris Inc, Medtronic PLC, and GSK plc. Recent corporate developments include FDA drug application acceptances and acquisitions. The ratings reflect varying levels of confidence from analysts with high accuracy rates.
